TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02130401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM (thermoneuromodulation device)
Description: The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
Study: NCT04284696

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pregnan-C-Gum(R) chewing gum
Description: Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewing gum
Description: Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum
Study: NCT02672371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active eMNS
Description: Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham eMNS
Description: Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
Study: NCT02869971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere® (Prostatic Arteries Embolization)
Description: Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug therapy
Description: Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
Study: NCT03603925

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Test / Magnetic Resonance (PET/MR)
Description: The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Test / Computed Tomography (PET/CT)
Description: Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
Study: NCT01338909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150mg/d starting from Day 1
Study: NCT00919932

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper and pen homework
Description: Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Text message system homework.
Description: Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
Study: NCT02628821

Intervention type: OTHER
Intervention: Preterm Infants treated with non-invasive ventilation.
Study: NCT03570307

Intervention type: OTHER
Group type: OTHER
Intervention: medical VS surgical evacuation of the uterus
Description: mentioned above

Intervention type: OTHER
Group type: OTHER
Intervention: medical VS surgical evacuation of the uterus
Description: mentioned above
Study: NCT03810027

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary
Study: NCT02844088

Intervention type: OTHER
Group type: OTHER
Intervention: Meningococcus C conjugate vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meningococcus C conjugate vaccine
Study: NCT04478188

Intervention type: OTHER
Intervention: Measuring Pressure Volume Loop Pre and Post Device Placement
Description: To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
Study: NCT01905176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In person education on heart failure topics before discharge
Description: Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone support and education post-discharge
Description: Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-discharge in person education and post-discharge telephone education and support
Description: Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
Study: NCT03858998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management Intervention
Description: A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Current routine HIV care in Tanzania.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Current routine HIV care in Tanzania.
Study: NCT02023983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge
Description: Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
Study: NCT02820324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT03239340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
Study: NCT02023983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard discharge
Description: Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
Study: NCT04751305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online delivered Exercise Classes
Description: The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online delivered Exercise Classes
Description: The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
Study: NCT02753894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral
Study: NCT03434873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: magnetic stimulation
Description: Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
Study: NCT02753894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral
Study: NCT02317159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400mg imatinib qd PO
Study: NCT01814176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope
Study: NCT03245021

Intervention type: DRUG
Group type: OTHER
Intervention: Opdivo
Description: All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles
Study: NCT01433471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris suis ova
Description: 2,500 eggs by mouth every two weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: 2,500 eggs by mouth every two weeks for 12 weeks
Study: NCT01567462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar electrocautery loop in Transurethral resection of bladder tumors
Description: Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
Study: NCT04182412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARD
Description: surgical reconstruction with laparoscopic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARD
Description: surgical reconstruction with laparoscopic technique
Study: NCT03607552

Intervention type: DEVICE
Intervention: Non-contrast DWI
Description: Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.

Intervention type: DEVICE
Intervention: Non-contrast MRI
Description: Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.

Intervention type: DEVICE
Intervention: Non-contrast MRI
Description: Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
Study: NCT06651138

Intervention type: RADIATION
Intervention: Fluoroscopy
Description: Pulsed or Continuous fluoroscopy during MILD procedure

Intervention type: RADIATION
Intervention: Fluoroscopy
Description: Pulsed or Continuous fluoroscopy during MILD procedure
Study: NCT03842475

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: Bariatric surgery
Study: NCT01567462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Description: PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
Study: NCT04395820

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: MBW

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: MBW

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MP-MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: MP-MRI
Study: NCT00479986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT05895448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .
Description: Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .
Description: Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
Study: NCT01973439

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 1: PK assessment while on Twice Daily Abacavir
Description: Week 0

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2: PK assessment while on Once Daily Abacavir
Description: Week 4
Study: NCT01445782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: Multiple dose, oral inhalation (nebuliser solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, oral inhalation (nebuliser solution)
Study: NCT03270657

Intervention type: DEVICE
Group type: OTHER
Intervention: IPG; RC+S
Description: We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
Study: NCT02056171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
Study: NCT02381080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
Study: NCT03218111

Intervention type: OTHER
Group type: OTHER
Intervention: MR Imaging
Description: All subjects will undergo six sessions of MR imaging over a 10-12 hour period

Intervention type: OTHER
Group type: OTHER
Intervention: CT-guidance
Description: All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
Study: NCT01700179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0143102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT00679341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
Study: NCT00779454

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, Oxaliplatin, Capecitabine,
Description: Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7

Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine
Description: Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
Study: NCT01455324

Intervention type: DEVICE
Intervention: Novel conformable woven inner socket
Description: Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
Study: NCT00002495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2 on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 on days 1 and 15

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard subtotal nodal irradiation
Description: 3600-4000 cGy delivered over 20 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard subtotal nodal irradiation
Description: 3600-4000 cGy delivered over 20 fractions
Study: NCT01567189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: * Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
Study: NCT01509794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Valence
Description: Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Valence
Description: Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
Study: NCT03917693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytin, rice extract
Description: Consumption of a rice extract, called phytin for a period of 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MCC, placebo
Description: Consumption of MCC, a placebo, for a period of 2 week
Study: NCT01164852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delivery
Description: Termination of pregnancy (delivery)after completed corticosteroids
Study: NCT01406691

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Flashes
Description: one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flashes
Description: one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime